ACTION PLAN AND MANAGEMENT ALGORITHM FOR PROLONGED JAUNDICE IN CHILDREN CONSIDERING MATERNAL METABOLIC STATUS
Keywords:
newborn, prolonged jaundice, bilirubin, maternal metabolism, obesity, cholestasis, risk factors.Abstract
This article examines the influence of maternal metabolic status on the development and clinical course of prolonged neonatal jaundice and presents an algorithm for diagnostic, therapeutic, and preventive measures. The study included 140 newborns with prolonged jaundice and their mothers.Background. Prolonged neonatal jaundice is a common condition in newborns, and its development may be associated not only with the individual characteristics of the infant but also with maternal metabolic status. Maternal obesity, lipid metabolism disorders, and intrahepatic cholestasis of pregnancy may increase the risk of impaired bilirubin metabolism and cholestasis in newborns.
Objective. To evaluate the influence of maternal metabolic abnormalities on the development and clinical course of prolonged neonatal jaundice and to develop an algorithm of diagnostic, therapeutic, and preventive measures based on an integrated “mother–infant” metabolic approach.
Materials and Methods. The study included 140 newborns with prolonged jaundice and their 140 mothers. Among the examined women, 40.7% (57) were overweight, 15.0% (21) had grade I–II obesity, 17.9% (25) were underweight, and 26.4% (37) had a normal body weight. Clinical, anthropometric, biochemical, and immunological examinations were performed in the mothers and newborns. Correlation analysis, odds ratios (ORs), and 95% confidence intervals (95% CIs) were used for statistical evaluation.
Results. The most significant maternal risk factors for prolonged neonatal jaundice were obesity (OR=23.27; 95% CI: 8.76–61.84), intrahepatic cholestasis of pregnancy (OR=15.07; 95% CI: 6.59–34.47), underweight (OR=5.29; 95% CI: 1.68–16.68), and a positive family history (OR=5.07; 95% CI: 2.29–11.23). Statistically significant correlations were identified between maternal total cholesterol and neonatal total bilirubin levels (r=0.49), the maternal atherogenic index and neonatal total bilirubin levels (r=0.45), and maternal low-density lipoprotein levels and neonatal direct bilirubin levels (r=0.52).
Conclusion. The findings demonstrate that prolonged neonatal jaundice should be assessed within the framework of an integrated “mother–infant” metabolic system. The proposed algorithm facilitates the early identification of high-risk groups, timely laboratory and instrumental examinations, and individualized monitoring and treatment strategies for newborns.
References
Kemper A.R., Newman T.B., Slaughter J.L. et al. Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. Pediatrics. 2022;150(3):e2022058859. doi:10.1542/peds.2022-058859.
Fawaz R., Baumann U., Ekong U. et al. Guideline for the Evaluation of Cholestatic Jaundice in Infants: Joint Recommendations of NASPGHAN and ESPGHAN. Journal of Pediatric Gastroenterology and Nutrition. 2017;64(1):154–168. doi:10.1097/MPG.0000000000001334.
National Institute for Health and Care Excellence. Jaundice in newborn babies under 28 days. Clinical guideline CG98. Updated 2023.
American Academy of Pediatrics. Hyperbilirubinemia: clinical guidance and implementation resources. 2022.
World Health Organization. Guideline: protecting, promoting and supporting breastfeeding in facilities providing maternity and newborn services. Geneva: WHO; 2017.
Sharipova S.M. Clinico-biochemical characteristics of prolonged jaundice in newborns born to mothers with metabolic syndrome: dissertation. Urgench; 2026.